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Abstract
Background: The impact of viral load (VL) decay and cumulative VL on CD4 recovery and AIDS after highly-active
antiretroviral therapy (HAART) is unknown.
Methods and Findings: Three virologic kinetic parameters (first year and overall exponential VL decay constants, and first
year VL slope) and cumulative VL during HAART were estimated for 2,278 patients who initiated HAART in the U.S. Military
HIV Natural History Study. CD4 and VL trajectories were computed using linear and nonlinear Generalized Estimating
Equations models. Multivariate Poisson and linear regression models were used to determine associations of VL parameters
with CD4 recovery, adjusted for factors known to correlate with immune recovery. Cumulative VL higher than the sample
median was independently associated with an increased risk of AIDS (relative risk 2.38, 95% confidence interval 1.56–3.62,
p,0.001). Among patients with VL suppression, first year VL decay and slope were independent predictors of early CD4
recovery (p=0.001) and overall gain (p,0.05). Despite VL suppression, those with slow decay during the first year of HAART
as well as during the entire therapy period (overall), in general, gained less CD4 cells compared to the other subjects (133 vs.
195.4 cells/mL; p=0.001) even after adjusting for potential confounders.
Conclusions: In a cohort with free access to healthcare, independent of established predictors of AIDS and CD4 recovery
during HAART, cumulative VL and virologic decay patterns were associated with AIDS and distinct aspects of CD4
reconstitution.
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Introduction
The initial goal of highly-active antiretroviral therapy (HAART)
was to improve AIDS-free survival and attempt to mitigate the
harmful effects of treatment. Immune reconstitution via CD4
recovery served as an intermediate marker for response to
HAART because of its predictive capacity for AIDS events and
death.[1,2,3] Thereafter, virologic suppression became the
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appropriate, early predictor of immunologic response and clinical
outcomes.[4,5,6,7] Furthermore, it was demonstrated that incom-
plete suppression of viral replication allowed for the emergence of
drug resistance and ultimately virologic failure.[8,9] These
findings led to recommendations in the U.S. Department of
Health and Human Services guidelines that patients should
achieve complete virologic suppression (viral load [VL] ,400 cop-
ies/mL by 24 weeks or ,50 copies/mL by 48 weeks) and
maintain suppression thereafter.[10]
Even among patients reaching these virologic targets, there
are significant inter-individual differences in the recovery of
CD4+ T cells and risk of clinical events, suggesting that other
factors may relate to these outcomes.[11,12,13,14,15,16]
Age at HAART initiation, pre-HAART VL and CD4 cell
count, magnitude of and time to VL suppression all have been
shown to influence CD4 recovery and clinical outcomes.
[4,13,17,18,19,20,21,22,23,24,25,26] Although the relationship
of virologic decay patterns with VL changes during HAART has
been described,[23,27,28,29] the impact of these decay patterns
on CD4 reconstitution and risk of subsequent clinical AIDS
events has not been fully elucidated. Furthermore, it is also
conceivable that the overall VL burden, represented as the
cumulative VL during HAART, may also influence CD4
recovery and risk of AIDS events. Hence, we determined
whether the patterns of virologic decay and the cumulative VL
during HAART were associated with AIDS and CD4 recovery
after HAART initiation independent of the currently recom-
mended dichotomous measures of VL suppression[10] within a
large, observational cohort with free access to medications and
care, high rates of adherence, and low rates of injection drug
use.[26,30] If virologic decay measures are independently
associated with outcomes, this could provide some explanation
as to why some individuals experience inadequate treatment
response despite achieving virologic suppression. Additionally,
cumulative viral load could serve as a sensitive marker for risk of
AIDS after HAART beyond traditional measures.
Materials and Methods
Study Participants
The U.S. Military HIV Natural History Study (NHS) is a
prospective multicenter observational study of HIV-infected active
duty military personnel and other beneficiaries (spouses, depen-
dents, and retired military personnel) from the Army, Navy/
Marines and Air Force. Seroconverters (SC) were defined as
patients having a documented HIV seronegative date prior to the
first positive HIV date (see Table S1). The estimated date of
seroconversion for SC was defined as the midpoint between the
two dates. All CD4 count, VL, and other measurements were done
as part of routine clinical care.[31] The clinically-approved
methodology for this testing varied by site and over time. Prior
ARV use referred to any antiretroviral therapy not meeting the
NHS definition of HAART.[26] HAART initiation was the date
when HAART was first prescribed.
Ethics Statement
Participants who provided written informed consent and
initiated HAART through July 1, 2008 regardless of regimen
continuation were included in the present study. The NHS and
this substudy have been approved by each center’s Institutional
Review Board and the Uniformed Services University of the
Health Sciences Institutional Review Board.
Statistical Analysis
VL Parameters. A primary aim of this study was to capture
andsummarizethe overallandearlyVLdynamicsinsuch amanner
as to permit their eventual use in clinical practice. In that regard, we
made the following assumptions: i) by the time HAART is typically
initiated for an individual in the NHS a natural steady state VL
exists; ii) once potent HAART is initiated there is a rapid decline in
the VLfollowed by a slowerdecline; and iii) such a typical patternof
VL can be explained on the basis of an exponential decay in the
circulating VL. The definitions of the parameters used in this study
are shown in Table S1, and the theoretical bases for the estimation
oftheseparametersarefurtherdescribedinNoteS1.The composite
‘‘virologic decay’’ refers to the application of an exponential decay
equation which has been fitted to all viral loads available for an
individual after the initiation of HAART. For a majority of
participants in this cohort who have a high level of adherence, the
virologic decay pattern corresponds to the concatenation of each
"classical" (first, second, etc.) phase of decay for that individual. For
some participants, their virologic decay does not follow these
patterns due to suboptimal adherence, inadequate drug levels, drug
resistance, and treatment interruption.
We computed four VL parameters at the level of each
individual: (i–ii) exponential decay constant of VL change during
entire duration of HAART (overall) and during the first year of
HAART, respectively; (iii) VL slope during the first year of
HAART obtained using linear Generalized Estimating Equations
(GEE) models; and (iv) cumulative VL (Table S1). The VL
parameters described above in i, ii, and iii are designated as VL
kinetic parameters. Similarly, we computed the following four
CD4 count parameters at the level of the individual: (i–ii) slope of
the CD4 count change during and after the first two years of
HAART; (iii) mean CD4 count after the first two years of
HAART; and (iv) overall gain in CD4 counts (Table S1).
Cohort level analyses. The cohort-level analyses made use
of all available CD4
+ T cell count and VL data for all subjects to
generate time-trend lines or curves using linear and non-linear
GEE models, assuming an equal correlation structure. The time-
trend curves derived by non-linear GEE modeling were refined
further using spline smoothed curves with knots at the end of each
year since HAART initiation. The resulting curves describe an
overall or composite VL pattern for the cohort.
Association analyses. We estimated the parameters detailed
in Table S1 for each individual. The association of these individual
level parameters with the risk of AIDS (defined using 1993 clinical
criteria[32] but did not include a CD4 count ,200 cells/mLa sa n
endpoint) was assessed by Poisson regression models, and with
recovery of CD4 counts by linear regression models. In these
models we accounted for the potential confounding due to VL
suppression by HAART by including two covariates - achievement
of VL suppression (as defined in Table S1) and the time taken to
achieve VL suppression from the start of HAART. As described in
the results, we ran these multivariate analyses for the VL
parameters that were estimated (i) by including all VL
measurements after HAART and separately (ii) by restricting to
only those measurements after HAART but prior to the
occurrence of the first AIDS event. Statistical significance was
evaluated at a type I error rate of 0.05. All statistical analyses were
conducted using Stata 7.0 (Stata Corp., College Station, TX).
Results
Cohort-level VL and CD4 changes after HAART initiation
Characteristics of the 2278 participants who initiated HAART
are in Table 1. The average follow up time after HAART for
Viral Load Decay Modeling
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GEE modeling of VL from time-of-HAART initiation in all
subjects revealed the following pattern: a precipitous decline in VL
during the first year, a temporary rebound at ,1.6 years post-
HAART, followed by a relatively steady-state VL thereafter
(Fig. 1A). The VL trajectory of subjects who developed AIDS
during HAART versus those who remained AIDS-free differed
significantly as a decline in VL after HAART initiation was not
observed in patients who developed AIDS (Fig. 1B). In all subjects
(Fig. 1C) and in those who attained VL suppression (Fig. 1D), VL
trajectories differed according to the tertiles of the pre-HAART
VL such that those who started with higher VLs (upper and
middle tertiles of pre-HAART VL) displayed a sharper decline in
VL than those subjects categorized to the lower pre-HAART VL
tertile (Fig. 1C-D, Table S2).
The cohort-level trajectories in CD4 counts during HAART
revealed two phases of CD4 count changes In phase I, for all
subjects initiating HAART there was a rapid increase in CD4
counts during the first two years, followed in phase II by a
slower, sustained gain in CD4 cells (Fig. 1A). We stratified the
cohort-level changes in CD4 count gains according to whether
subjects attained VL suppression (Fig. 1E). This analysis
revealed that during the first year of HAART, rapid and similar
gains in CD4 counts (,200 cells on average) were observed in
those who did (brown curve) or did not (black curve) attain VL
suppression (Fig. 1E). However, in contrast to those who
attained VL suppression, the initial gains in CD4 counts were
not durable among those who did not achieve VL suppression
(Fig. 1E).
VL kinetic parameters and AIDS risk after HAART
The association of the three VL kinetic parameters and
cumulative VL with risk of developing AIDS during HAART
was evaluated in separate multivariate models adjusted for length
of follow up. For these and the other analyses described later, we
dichotomized subjects based on the VL parameters using the
median value of the parameter as the cut-off. We included into
each multivariate model additional covariates that have been
shown to be predictive of immunologic recovery during HAART,
including time to VL suppression (Table 2).[26,33,34,35,36,37,38]
Nadir CD4 was used as a surrogate for pre-HAART CD4 counts
because the median time from the nadir CD4 to HAART
initiation was short (Table 1).
The slope and exponential decay constant for VL during the
first year of HAART were not predictive of AIDS, whereas a
slower overall VL decay showed a statistical trend towards
predicting AIDS during HAART, independent of the other
covariates (RR 1.38, p=0.058). A higher than average cumulative
VL during HAART (RR=2.38, 95% CI=1.56–3.62) was
associated with the greatest risk of developing AIDS. These results
were similar when the VL parameters were estimated excluding
the VL measurements recorded after the AIDS event occurred
(Table 2) or when the analyses were restricted to seroconverters
only (Table S3).
In separate analyses, where attainment of VL suppression at any
point during HAART was replaced with VL suppression by 6 or
12 months, overall VL decay constant was a significant
independent predictor of AIDS in patients who attained VL
suppression at 6 (RR=1.65, p=0.007, 95% CI=1.14–2.38) and
12 (RR=1.43, p=0.055, 95% CI=0.99–2.05) months, whereas
in these models, the VL slope or exponential VL decay during the
first year were not predictive of AIDS. The cumulative VL
remained highly predictive of AIDS risk in those who attained VL
suppression during 6 (RR=1.96, p=0.004, 95% CI=1.24–3.13)
and 12 (RR=2.33, p=0.001, 95% CI=1.44–3.80) months of
HAART. Collectively, these data indicated that a slow overall VL
exponential decay and a high cumulative VL during HAART
increased AIDS risk after initiation of HAART.
VL parameters and CD4 Recovery
We next determined whether the VL kinetic and other
parameters that were included in the models to assess AIDS risk
during HAART also associated with the rate of CD4 gain
(Table 3). We found that the VL parameters predicted different
aspects of CD4 count recovery even after accounting for factors
that we found to be highly predictive of AIDS risk, including prior
Table 1. Characteristics of subjects on HAART studied.
Characteristic n
a
Median (IQR) or
Percentage
Age at HAART (y) 2275 34.27 (29.15–39.61)
Female gender 2278 188 (8.3%)
Ethnicity 2278
European Americans 1006 (44.2%)
African Americans 1003 (44.0%)
Hispanic Americans 186 (8.2%)
Others 83 (3.6%)
Baseline CD4 (cells/ml) 2284 466 (330–637)
Nadir CD4 (cells/ml) 2200 278 (167–378)
Time from nadir CD4 to HAART initiation (y) 2200 0.26 (0.03–1.34)
Baseline VL (log10 copies/ml) 1951 4.38 (3.75–4.88)
Pre HAART VL (log10 copies/ml) 1799 4.35 (3.76–4.85)
Overall VL decay constant (x10
22) 2055 2.57 (21.19–7.06)
VL decay constant during year one of
HAART (x10
22)
1684 5.22 (27.8–55.2)
VL slope (log10 copies/ml/month) during
year one of HAART
1684 0.16 (20.26–1.42)
Cumulative VL (log10 copies*months/ml) 1949 16.31 (7.14–24.94)
Average time to HAART initiation (y) 2278 3.60 (0.46–7.88)
Late HAART era 2278 1579 (69.3%)
Prior use of ARV 2278 1087 (47.7%)
AIDS before HAART initiation 2278 139 (6.1%)
Duration of follow-up on HAART (y)
b 2278 5.63
VL measurements per individual per year
b 2278 3.07
CD4 measurements per individual per year
b 2278 2.65
AIDS after HAART (%) 2278 12.27%
VL suppression
Ever 2278 1925 (84.5%)
First twelve months 1722 1113 (64.6%)
First six months 1790 1178 (65.8%)
First three months 1294 837 (64.7%)
CD4 slope in first 2 years after HAART
(cells/ml/year)
1931 56.6 (218.0–128.8)
CD4 slope after 2 years of HAART
(cells/ml/year)
1532 3.55 (225.3–34.2)
Mean CD4 count 2 years after HAART
(cells/ml)
1560 533.4 (351.1–712)
an, number of subjects on whom indicated data was available.
bvalues represent the mean.
doi:10.1371/journal.pone.0017956.t001
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VL suppression. The overall decay rate constant was not
predictive of rate of CD4 gain in the first 2 years, but was
significantly associated with the rate of CD4 gain after two years of
HAART, the mean CD4 count two years after HAART, and the
overall gain of CD4 cells (Table 3). The decay constant and VL
slope in the first year of HAART were mostly predictive of the rate
of CD4 cell gain during the first two years and the overall gain in
CD4 cells (Table 3). By contrast, the cumulative VL was only
predictive of rate of CD4 gains after 2 years and not the overall
gain in the CD4 count (Table 3).
The aforementioned data suggested that a slower VL decay
during the first year of HAART is associated with both a reduced
rate of CD4 gain in the first two years of HAART and overall gain
in CD4 cells (Table 3). By contrast, a slower overall VL decay is
more predictive of a reduced rate of CD4 gain after 2 years of
HAART, lower mean gains in CD4 counts after 2 years of
HAART as well as a reduced overall gain in CD4 cells (Table 3).
On the basis of these results, we posited that VL suppressers who
had a slow VL decay in the first year of HAART and the entire
therapy course (overall) would fare the worst with respect to CD4
recovery. To test this, we categorized VL suppressors into two
Figure 1. CD4+ T cell count and VL trajectories during HAART. (A) Overall (population level) VL and CD4 trajectories after HAART initiation.
The curves for CD4 counts (blue and corresponding to the right Y axis) and VL (red and corresponding to the left Y-axis) are superimposed to provide
a common temporal view of the trajectories from time of HAART initiation (x-axis). (B) VL trajectories in subjects who developed or did not develop
AIDS during HAART. (C–D) VL trajectories after HAART initiation based on the tertiles of pre-HAART VL in (C) all subjects and (D) those who achieved
VL suppression. (E–F) CD4+ T cell count trajectories after initiation of HAART according to (E) attainment of VL suppression and (F) VL kinetics among
VL suppressers. In panel F, slow/slow indicates subjects who had slow (less than median) rate of VL decay estimated either using all the VL
measurements or using those during the first year after HAART initiation. The remaining three groups (rapid/slow, slow/rapid and rapid/rapid)
showed similar trajectories and were, therefore, grouped into a single category. All trajectories shown were modeled using non-linear GEE and spline
smoothing assuming equal-correlation structure. In panels, A, B, E and F the central thick line represents the mean and the two straddling thin lines
represent the edge of the 95% confidence interval band. N, number of subjects; M, number of CD4 or VL measurements.
doi:10.1371/journal.pone.0017956.g001
Viral Load Decay Modeling
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decay were categorized into one group, whereas the remainder
(rapid/rapid, rapid/slow, slow/rapid decay in the first year and
overall decay, respectively) were grouped together because they
had very similar CD4 count trajectories (data not shown). Subjects
categorized to the slow early/slow overall decay group were
similar to other subjects with respect to age at HAART initiation,
ethnicity and nadir CD4 (all p values .0.2).
Notably, VL suppressers categorized to the slow/slow decay
group had a significantly muted CD4 recovery during HAART
compared with all other subjects (Fig. 1F). Concordantly, VL
suppressors categorized to the slow/slow decay category had a
slower rate of CD4 recovery in the first two years (54.6 vs.
80.2 cells/mL/yr, p=0.02) and after two years (214.8 vs.
16.5 cells/mL/yr, p=0.002) of HAART, a lower mean CD4
count after two years (564.6 vs. 614.8 cells/mL, p=0.005) and a
lower absolute CD4 gain (133 vs. 195.4 cells/mL p=0.001). We
also conducted these analyses for subjects who achieved VL
suppression within 6 and 12 months and found highly concordant
results (data not shown).
Discussion
Not all patients on HAART display robust CD4 cell gains,
despite VL suppression.[11,12,13,14,15,16] This has been attrib-
uted previously to factors such as pre-HAART VL and nadir
CD4, age at HAART initiation, and depth of and time to VL
suppression. In this study, we modeled the VL decay and
cumulative VL and applied these relatively unique parameters to
a large well-characterized cohort in order to determine whether
these factors were associated with AIDS risk and CD4 recovery
during HAART independent of currently recommended bench-
marks of VL suppression at 6 and 12 months.[10] In the
participants that we evaluated, the initiation of HAART was
associated with a predictable decline in VL that was concomitantly
associated with an increase in CD4 counts. Subjects who did or
did not achieve VL suppression both experienced, on average, a
gain of 200 CD4 cells/mL during the first year of HAART.
However, in contrast to those who attained VL suppression, these
gains were not sustainable among non-VL suppressers. Notwith-
standing the importance of attaining VL suppression or minimiz-
ing the time to VL suppression, our data show that in addition to
these endpoints, both a slow early (first year of HAART) and slow
overall (during entire treatment period) VL decay were indepen-
dently associated with both a slower rate of and lower absolute
CD4 cell gain during HAART. Furthermore, a slower overall VL
decay in those who attained VL suppression within 6 and 12
months of HAART initiation, and a higher cumulative VL during
HAART were each independent predictors of increased AIDS risk
during HAART. These findings suggest that the patterns of VL
decay are important factors in addition to VL suppression for CD4
reconstitution and risk of AIDS during HAART.
The pre-HAART VL predicted the subsequent rate of decay
during the first year of HAART. Since most patients were able to
achieve suppression by 6–12 months, it is not surprising that the
rate of decay would be greater for patients with higher initial VLs.
This may also suggest that patients with higher initial VLs have a
larger proportion of actively replicating, productively-infected cells
that are more susceptible to HAART. This is consistent with
previous studies that examined decay for patients receiving
HAART.[39] It was also intriguing that the cohort-level analyses
also revealed that after the initial precipitous decline in VL there
was a transient rebound, regardless of initial VL (Fig. 1C). This is
due to a combination of individual profiles including a proportion
of patients experiencing virologic rebound with subsequent
resuppression, a small percentage experiencing rebound and not
achieving resuppression, and some patients experiencing blips. It is
unclear if this temporary, population-level rebound represents a
specific temporal relationship with average time to medication
fatigue and/or the development of virologic drug resistance as
nearly half of treated patients experience a change in therapy
around this time both as reported in this cohort[26] and
elsewhere.[40] Even in the absence of complete rebound from
poor adherence or drug resistance, periods of increased replication
can occur due to pharmacologic changes or altered drug activity in
a particular compartment.[29] Modeling data from structured
treatment interruption trials have shown that parametric reso-
nance, such as that seen in our study, can occur even in the
Table 2. Association of VL parameters with risk of AIDS development after initiation of HAART
a.
VL parameter Unadjusted Adjusted
RR 95% CI p RR 95% CI p
VL parameters using all available measurements
Overall decay constant 1.32 0.96–1.82 0.087 1.38 0.99–1.94 0.058
Decay constant in first year 1.03 0.72–1.47 0.876 1.07 0.74–1.55 0.730
Slope in first year 0.99 0.69–1.42 0.964 1.04 0.72–1.51 0.828
Cumulative VL 2.22 1.56–3.13 ,0.001 2.38 1.56–3.62 ,0.001
VL parameters by excluding measurements after first AIDS event
Overall decay constant 1.29 0.94–1.77 0.122 1.35 0.97–1.89 0.080
Decay constant in first year 1.05 0.73–1.50 0.795 1.07 0.73–1.55 0.732
Slope in first year 1.05 0.73–1.49 0.805 1.05 0.72–1.52 0.801
Cumulative VL 2.22 1.57–3.13 ,0.001 2.38 1.56–3.62 ,0.001
aResults are from a Poisson regression model adjusted for the length of follow-up. Unadjusted results are from the bivariate models with the indicated VL parameter as
the predictor and AIDS development as the outcome. All VL parameters were dichotomized based on their respective medians. The RRs are for the association of slow
decay (as indicated by less than median decay constants and slope) and high (greater than median) cumulative viral load with AIDS development. Adjusted models are
multivariate models that included the following covariates: baseline and nadir CD4 count, pre-HAART VL, time to HAART, age at HAART initiation (per 10 years) and
time to VL suppression were included as continuous variables.
doi:10.1371/journal.pone.0017956.t002
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This phenomenon can be seen when a system undergoing small
oscillations over time (such as during the dynamic equilibrium of
viral load setpoint) undergoes a significant dampening (HAART
initiation) and then experiences brief periods of external
perturbation (brief treatment interruptions).
Although the importance of early virologic suppression and
virologic failure on CD4 recovery has been well-de-
scribed,[21,22,24,42,43,44] much less is known about the impact
of rate of decay or detectable VL after initial suppression of VL on
CD4 recovery.[25,38,45,46,47,48] In this study, we incorporated
several of these elements into a single parameter of overall
virologic decay. This parameter provides information on the early
trajectory as well as the durability of the VL response after the
initial decay. We also evaluated cumulative VL because it could be
argued that it is the overall exposure to virus that influences CD4
recovery and AIDS.[38,49,50,51] We found that cumulative VL
was a stronger predictor of AIDS risk than CD4 recovery after
HAART initiation. Additionally, VL decay or slope within the first
year of HAART was not predictive of AIDS, whereas the overall
VL decay predicted AIDS even among patients who attained VL
suppression during 6 and 12 months of HAART. Thus, it is
striking that the risk of AIDS is not impacted by the initial rapid
phase of virologic decay, but rather by longitudinal assessments
such as the overall decay or cumulative VL. These findings suggest
that risk of AIDS during HAART is more sensitive to the VL over
time rather than events that occur during the first year of HAART
as has been suggested previously.[52,53,54,55] In contrast to this
study which examined the impact after HAART, Cole et al.
recently found that cumulative VL predicted AIDS or death in
absence of HAART independent of known risk factors in the
Multicenter AIDS Cohort Study.[56] As the number of serious
non-AIDS events during HAART increases relative to the number
of AIDS events over time, it will be important to determine the
association of overall virologic decay and cumulative VL with
serious non-AIDS events as has been demonstrated with
cancer[57,58] and renal impairment.[59] This data would also
suggest that perhaps the cumulative VL even prior to HAART
could be associated with clinical events during HAART,
supporting the notion that earlier diagnosis and treatment would
further reduce the number of these adverse outcomes.
Even among subjects who attained VL suppression, and after
adjustment for time to VL suppression, a slow overall VL decay
was predictive of late/long-term CD4 changes (rate of CD4 gain,
mean CD4 count after two years of HAART, and overall gain in
CD4 cells), but not early CD4 changes (rate of CD4 gain during
the first two years of HAART). In contrast, a slower VL decay
within the first year of HAART associated with early but not
later/long-term CD4 changes during HAART. These results
suggest that, although among VL suppressers the pace and extent
of CD4 gain during the early phases of HAART may be highly
correlated with both the early and overall VL decay patterns,
durable gains in CD4 cells after two years of HAART may be
highly dependent on the overall VL decay pattern. These findings
demonstrated that VL suppressors could be stratified into two
categories such that those with both a slow early and overall VL
decay (slow early/slow overall decay) will achieve CD4 recovery,
but the gain in CD4 cells would be significantly muted relative to
Table 3. Association of VL parameters with CD4 recovery after HAART initiation in subjects who did not develop AIDS.
Outcomes and Adjustment
Overall decay
constant
Decay constantin
first year Slope in first year Cumulative VL
Coeff (SE) p Coeff (SE) p Coeff (SE) p Coeff (SE) p
Model 1: Rate of CD4 gain in
first 2 years (cells/ml/year)
All subjects 6.98 (9.29) 0.453 32.01 (10.43) 0.002 32.69 (10.43) 0.002 22.52 (11.38) 0.824
VL suppressors 3.32 (9.29) 0.721 33.22 (10.42) 0.001 33.91 (10.42) 0.001 20.06 (11.60) 0.996
Seroconverters 1.12 (10.54) 0.915 33.09 (11.67) 0.005 33.12 (11.67) 0.005 9.39 (13.00) 0.470
Model 2: Rate of CD4 gain
after 2 years (cells/ml/year)
All subjects 40.59 (8.46) ,0.001 25.29 (9.86) 0.592 26.34 (9.87) 0.521 52.19 (10.87) ,0.001
VL suppressors 41.31 (8.61) ,0.001 26.43 (10.02) 0.521 27.50 (10.03) 0.455 52.92 (11.09) ,0.001
Seroconverters 43.59 (9.87) ,0.001 21.81 (11.34) 0.873 23.19 (11.36) 0.779 50.59 (12.47) ,0.001
Model 3: Mean CD4 count
2 years after HAART (cells/ml)
All subjects 40.21 (14.40) 0.004 33.67 (16.00) 0.036 24.42 (16.03) 0.128 24.54 (17.52) 0.795
VL suppressors 24.97 (14.10) 0.077 23.87 (16.02) 0.137 14.39 (16.05) 0.370 10.31 (17.65) 0.559
Seroconverters 32.08 (15.66) 0.041 34.36 (17.58) 0.051 22.93 (17.62) 0.194 9.72 (19.23) 0.613
Model 4: Overall gain of
CD4 cells (cells/ml)
All subjects 53.62 (17.45) 0.002 41.77 (18.80) 0.027 38.77 (18.81) 0.040 1.78 (24.11) 0.941
VL suppressors 51.06 (17.49) 0.004 40.35 (18.96) 0.034 37.53 (18.95) 0.048 13.13 (24.55) 0.593
Seroconverters 43.78 (19.40) 0.025 47.42 (20.54) 0.021 42.31 (20.57) 0.040 29.31 (26.49) 0.269
The results are from multivariate linear regression models, and shown are the linear regression coefficients and their standard errors along with significance values. Each
model set has three models for the indicated subjects. Each model is adjusted for covariates that in previous analyses were shown to associate with risko fA I D Sa n d
were age at HAART initiation, gender, time from entry into cohort to HAART initiation, African American ethnicity, previous receipt of ARV, AIDS prior to HAART,
pre-HAART VL, time to VL suppression and late HAART era (after 2000; Marconi et al).
doi:10.1371/journal.pone.0017956.t003
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polymorphisms that track the durability of CD4 recovery, it will
be important to evaluate whether the patterns of VL decay are in
part related to such host factors.[11]
The association of the extent of CD4 recovery was strongest
with the overall VL decay and not the first year VL decay or the
cumulative VL, suggests that these VL parameters may be
capturing different aspects of VL changes during HAART (early
trajectory and maintenance of suppression). The overall decay
provides information throughout the duration of treatment and is
not limited to one year of information. Hence, it is probable that
the decay pattern occurring after virologic suppression (third phase
of VL decay)[60] indexed to the decay patterns that occur
immediately after HAART initiation[23] together contribute to
the ability of a patient to experience durable immune reconstitu-
tion. It remains unclear if the latter phases of immune
reconstitution are affected by ‘‘blips’’ or primarily by more
substantial viral rebound.[61,62]
In contrast to the overall decay pattern, the cumulative VL is a
coarse measure of overall VL burden (total virus exposure) during
HAART and does not account for VL decay patterns. For
example, a patient who suppresses early but has late rebound
might have a comparable cumulative VL to that of a patient with
predominantly late virologic suppression. This may partly explain
why this parameter as computed may not associate strongly with
CD4 recovery. However, another explanation hinges on the use of
detectable VLs to compute this parameter. Certainly, patients with
complete or repetitive virologic rebounds may experience a loss of
CD4 recovery; however, the vast majority of patients in this cohort
achieved suppression within the first year and the rate of rebound
was low.[26] Therefore, at the frequency of available measure-
ments, the cumulative VL may not capture some of the
intermittent or ongoing low-level viremia during HAART which
may represent actual viral replication in the setting of periodic
HAART interruption. Hence, it is conceivable that computation
of the cumulative VL using more frequent measurements and/or
single copy assays that assess VL below the detectable threshold of
commercial assays might reveal that the cumulative VL is a more
sensitive marker of not only AIDS risk but also CD4 recovery.
We investigated a large number of prospectively evaluated
subjects who have equal access to healthcare and high rates of
adherence to HAART.[26,30] This afforded an excellent
opportunity to observe the impact of virologic parameters on
CD4 recovery in a setting outside of a clinical trial, making these
results more generalizable to the HIV-infected population at large.
There are some limitations of this study. This study did not
attempt to dissect the components of the VL decay[24,63] and
determine what baseline and subsequent factors contribute to
these components. For example, different regimens, the existence
of drug resistance, variable pharmacokinetics and adherence
patterns can result in different rates for the first and second phases
of VL decay, respectively.[24,28] To this end, we used HAART
era as a covariate in the multivariate model to adjust for regimen
potency and prior single or dual ART. Furthermore, although
rates of adherence in this cohort[26] are high, the rationale of
these analyses was not to understand the impact of adherence on
the rate of decay but instead how the decay patterns alone
influence subsequent clinical/immunologic outcomes regardless of
the level of adherence which in a clinical setting can often be
unreliable. We also acknowledge that we studied a total of 52
multivariate models (shown in Tables 2 and 3) and at a global type
I error rate of 0.05, 2–3 observed associations are likely to be
erroneous. Given the fact, however, that we observed a total of 23
associations to be significant at 0.05 type I error rate, our study
results are unlikely to have been influenced by false positive
associations due to multiple testing. Finally, although the impact of
drug resistance and pharmacokinetic interactions was not
examined in this study, prior ARV use was used as a surrogate
marker of baseline resistance in the multivariate models.
In summary, our findings underscore that the early and overall
patterns of VL decay among VL suppressed patients is an
independent determinant of CD4 recovery. In addition, the
cumulative VL is a determinant of AIDS risk during HAART.
Thus, inter-individual differences in VL decay patterns may partly
explain the wide variability in CD4 recovery even among those
individuals achieving VL suppression within the recommended
timeframe. These results also suggest that regimens that produce
the most rapid virologic decay and durable suppression could lead
to better clinical/immunologic responses. These parameters could
be further developed to enhance clinical trial assessment of ARV
regimens and assist clinicians with identifying patients at risk for
adverse events beyond standard indicators.
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